Southern Research Institute

Biocryst Pharmaceuticals, Inc.

The United States of America As Represented by the Department of Health

Biocryst, Inc.

Other

The United States of America

USA As Represented by Secretary of the Navy

The United States of America As Represented by the Secretary of

Sloan-kettering Institute for Cancer Research

The Government of the United States of America

Biocryst Pharmacueticals, Inc.

Ciba-geigy Corporation

John A., Iii Secrist

Mark D. Erion

Steven E. Ealick

John A Montgomery

John A Secrist, Iii

Carroll G Temple, Jr

Robert D Elliott

Mark D Erion

Kamal N Tiwari

Steve E Ealick

Wayne C Guida

James R Piper

Glynn P Wheeler

Yarlagadda Sudhakara Babu

Pooran Chand

Philip E Morris, Jr

William L Hinds, Jr, Legal Representative

Francis M Sirotnak

Shanta Bantia

Anita T Fowler

Shri Niwas

Peter K Chiang

Jerry D Rose

Iii Secrist John A

Peter Anthony Crooks

Pravin L Kotian

Joseph I DeGraw

Joseph A Maddry

Jack D Ayers

William B Parker

Robert C Reynolds

William M Shannon

David I Scheer

Brandon Powell

Charles A Krauth

Giulio L Cantoni

John P Bader

H Jeanette Thomas

Guilio L Cantoni

Anita T Shortnacy

Geetha Vasanthakumar

Sarah D Clayton

Gregory Cowart

George A Omura

L Lee Bennett

Y Fumer Shealy

Steven E Ealick

John A Iii Secrist

A method to improve thermal performance of vascular composites by using a two-phase working fluid for isothermalization includes the steps of: manufacturing a vascular composite structure optimized for a design point; manufacturing a thermal back end sized for the application; integrating the vascular composite into a fluid loop; and evacuating and filling the fluid loop with working fluid to an amount resulting in two-phase operation at the design point.

Two-phase cooling in vascular composites using a pumped fluid loop

A break-away camera mount comprising a support for supporting a camera case steadily above the surfboard, first and second magnetic connectors each configured to magnetically engage each other, but permit detachment upon sufficient shear and/or transverse force being applied to the mount, a base configured to secure the first magnetic connector to the surfboard, and a tether connecting the second magnetic connector to the surfboard.

Breakaway magnetic mount

Patients suffering from cancer are treated by being administered a compound represented by the following formula:  

Preparation of thioarabinofuranosyl compounds and use thereof

Compounds represented by the formula 1:  

4'-thio-L-xyloy furanosyl nucleosides, precursors thereof, preparation and use thereof

2-Chloro-9-(2-deoxy-2-fluoro-&#x3b2;-D-arabinofuranosyl)-9H-purin-6-amine is synthesized by reacting a 2-chloro-6-substituted purine with a protected and activated 2-deoxy-2-fluoro-D-arabinofiranose; and reacting with a base such as ammonia to provide 2-chloro-9-(2-deoxy-2-fluoro-&#x3b2;-D-arabinofuranosyl)-9H-purin-6-amine. When the purine reactant is substituted in the 6 position with a halogen, a reaction step with an alkoxide is carried out prior to the reaction with ammonia.

[object Object]

4'-thio-L-xylo furanosyl nucleosides, precursors thereof, preparation and use thereof

Thioarabinofuranosyl compounds and use thereof

2-Chloro-9-(2-deoxy-2-fluoro-&#x3b2;-D-arabinofuranosyl)-9H-purin-9-amine is synthesized by reacting a 2-chloro-6-substituted purine with a protected and activated 2-deoxy-2-fluoro-D-arabinofuranose; and reacting with a base such as ammonia to provide 2-chloro-9-(2-deoxy-2-fluoro-&#x3b2;-D-arabinofuranosyl)-9H-purin-6-amine. When the purine reactant is substituted in the 6 position with a halogen, a reaction step with an alkoxide is carried out prior to the reaction with ammonia.

Method for synthesizing 2-chloro-9-(2-fluoro-&#x3b2;-D-arabinofuranosyl)-9H-purin-6-amine

Compounds represented by the formula 1: A is selected from the group consisting of

4'-thio-L-xylofuranosyl nucleosides, precursors thereof, preparation and use thereof

Patients suffering from cancer are treated by being administered a compound represented by the following formula:

T-cell inhibition proliferation in a mammalian host by administering effective amounts of 2&prime;-deoxyguanosine and/or prodrugs thereof; and certain PNP inhibitors.

Inhibiting T-Cell proliferation

Enhancement of T-cell proliferation in a host inhibition is provided by administering 2&prime;-deoxyguanosine and/or prodrug thereof and a PNP inhibitor. The PNP inhibitor has a Ki value of 50 nanomoles or less.

Inhibiting T-cell proliferation

Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors

Growing community of inventors

Birmingham, AL, United States of America

John A Montgomery